New Spherix research highlights existing need for innovation in this underserved population
EXTON, Pa., May 22, 2023 /PRNewswire/ — The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S. Despite the significant size and unmet need of the potential market, pharmaceutical companies have yet to capitalize on the opportunity.
History is littered with failed NAFLD/NASH clinical trials, with last Friday’s Gastrointestinal Disease Advisory Committee (GIDAC) potentially serving up another, as it denied Intercept Pharmaceutical’s accelerated approval for Obeticholic Acid (OCA) to treat NASH. While OCA may still have a chance to find its way to patients, the advisory committee voted 12 to 2 against the risk benefit profile offered by the potential therapy.